Physician profile
Candice E Whealon
NPI 1790830404
$4,921.79
in general payments reported to CMS, 2019-2025
17 companies · $2,467 in 2025
The $2,467 reported for 2025 was more than what 99% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $533 · 2023: $1,099 · 2024: $394 · 2025: $2,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $1,559.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,614.01 | 2024-2025 | Blujepa |
| Abbvie INC. | $346.57 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.30 | 2021-2023 | |
| Sage Therapeutics, LLC | $229.43 | 2023 | |
| Edwards Lifesciences Corporation | $131.19 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Neurocrine Biosciences, INC. | $126.44 | 2024 | Ingrezza |
| Astrazeneca Pharmaceuticals Lp | $125.27 | 2023 | |
| Neurelis, INC. | $125.00 | 2023 | Valtoco |
| Lucid Diagnostics INC. | $124.59 | 2022 | |
| Sk Life Science, INC. | $123.86 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $121.63 | 2022 | |
| Argenx US, INC. | $120.86 | 2023 | Vyvgart |
| Teva Pharmaceuticals USA, INC. | $120.79 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $120.39 | 2024 | |
| Dexcom, INC. | $87.73 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $85.12 | 2022 | |
| Abbott Laboratories | $77.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Whealon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.